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Summary. Viral antibodies were tested in a cohort of 44 islet- 
cell antibody-positive individuals age 7-19 years, and 44 of 
their islet cell antibody-negative age and sex-matched class- 
mates selected from a population study of 4208 pupils who 
had been screened for islet cell antibodies. Anti-coxsackie 
B1-5 IgM responses were detected in 14 of 44 (32 %) of the 
islet cell antibody-positive subjects and in 7 of 44 (16 % ) con- 
trol subjects. This difference did not reach the level of statis- 
tical significance. None of the islet cell antibody-positive sub- 
jects had specific IgM antibodies to mumps, rubella, or 
cytomegalovirus. There was also no increase in the pre- 
valence or the mean titres of anti-mumps-IgG or IgA and 
anti-cytomegalovirus-IgG in islet cell antibody-positive 
subjects compared to control subjects. These results do not 
suggest any association between islet cell antibodies, and 
possibly insulitis, with recent mumps, rubella or cytomegalo- 
virus infection. Further studies are required to clarify the re- 
lationship between islet cell antibodies and coxsackie B virus 
infections. 
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There is considerable evidence implicating virus infection 
in the pathogenesis of Type 1 (insulin-dependent) 
diabetes mellitus, particularly infection with coxsackie B
and other enteroviruses, but also mumps, rubella and cy- 
tomegalovirus. This evidence is based on studies in animal 
models [1], anecdotal case reports in which viruses have 
been isolated from patients at the time of Type 1 diabetes 
onset [2-4] and seroepidemiological studies to determine 
the prevalence of virus-specific IgM responses in patients 
with recently diagnosed Type 1 diabetes [5-9], indicating 
that virus infection is present in a proportion of patients 
around the time of diabetes onset. In view of the long incu- 
bation period before clinical diabetes becomes apparent 
in man, it is pertinent o consider whether virus infection 
may be involved in the initiation of the disease process, 
rather than simply the precipitation of disease in patients 
with already compromised Beta-cell function. To this end 
we have sought evidence of virus infection in healthy 
schoolchildren with islet cell antibodies (ICA), a pre- 
diabetic serological marker [10-14]. This study forms part 
of a wider study to assess additional makers of the pre- 
diabetic state, and their relationship to the presence of 
ICA [15]. 
Subjects and methods  
Study population 
Between July 1988 and July 1989, 4208 students (age range 7-21 
years; mean age 13.9 years) from 19 schools in Ulm/Alb-Donau 
County, FRG, were investigated. The aim of this study was to screen 
for markers which maybe associated with Type 1 diabetes, and to 
define the frequency of certain viral antibodies associated with the 
presence of ICA. The study was performed in accordance with the
principles of the Declaration of Helsinki. Sera were stored at - 20 ~ 
until they were used for further testing. 
Of the 4208 pupils tested 44 (1.05%) were positive for ICA. 
These ICA-positive individuals were selected for antiviral antibody 
determination. The median age of ICA-positive subjects was 
13.5 years (range 7-19 years). Six of the 44 (13.6 % ) were positive for 
complement-fixing ICA. 
Control subjects 
For each ICA-positive individual, an age and sex-matched class- 
mate was selected, the serum sample being collected onthe same day 
as that of the proband. 
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Tab le  1 .  Ant i -v i ra l  ant ibod ies  in  i s le t  ce l l  ant ibody-pos i t ive  and  in  i s le t  ce l l  ant ibody-negat ive  non-d iabet ic  p robands  
Pat ients  ICA-pos i t ive  probands  ICA-negat ive  cont ro l  sub jec ts  
No  Age  Sex  CBV mumps CMV rube l la  CBV mumps CMV rube l la  
IgM IgM IgG IgM IgG IgM H I  IgM IgM IgG IgM IgG IgM H I  
1 8 M + - + . . . . . . . . . . .  
2 9 M . . . . . . . . .  + - + - + 
3 11  M . . . . . . . .  + - + - + 
4 12  M - - + - - - + - - + - - - + 
5 12  M . . . . . .  + + - - - + - + 
6 12  M - - + - - - + - - + - - - + 
7 12  M - - + - - - + - - + - - - + 
8 12  M - - + - - * + - - + . . . .  
9 13  M - - + - + - + . . . .  + - + 
10  13  M - - + - - - + . . . . . .  + 
11 13  M + - + - + - + - - + . . . .  
12  13  M - - + - - - + - - + - + - + 
13  13  M - - + - + - + - - + - - - + 
14  14  M - - + - - - + - - + . . . .  
15  14  M + - + - - - + . . . . . . .  
16  14  M + - + - - - + . . . . . .  + 
17  14  M - - + . . . . . .  + - + - + 
18  14  M - - + - - - + - - + - + - + 
19 15  M - - + - - - + - - + - - - + 
20  16  M . . . . . . . . .  + - + - + 
21  16  M - - + - - - + - - + - + - + 
22  16  M - - + - - - + - - + - - - + 
23  17  M - - + - + . . . . . . . .  + 
24  17  M - - + - - - + - - + - + - + 
25  17  M - - + . . . . . .  + - - - + 
26  7 F + - + - - - + - - + - - - + 
27  7 F - - + - - - + + - + - - - + 
28  8 F + - + - - - + - - + . . . .  
29  10  F + - + - + - + . . . .  + - - 
30  10  F - - + . . . .  + - + - - - + 
31  11  F - - + - - - + + - + - + - + 
32  11  F + - - - + . . . . . . . . .  
33  12  F + - + - - * + - - + - - - + 
34  12  F + - + - + - + - - + - - - + 
35  13  F + - + - + - + - - + - - + + 
36  13  F + - - - + - + - - + - - - + 
37  14  F + - + - - - + . . . . . .  + 
38  14  F - - + - - - + + . . . . .  + 
39  14  F - - + - - - + + - + - - - + 
40  15  F - - + - - - + - - + - - - + 
41  15  F - - + - - - + - - + . . . .  
42  16  F - - + - - - + + . . . . .  + 
43  16  F - - + . . . . . .  + - - - + 
44  19  F + - + - - - + - - + - - - + 
Z 14  0 38  0 9 0 35  7 0 32  0 12  0 35 
% 32  0 86  0 20  0 80  16  0 73  0 27  0 80  
CBV,  coxsack ie  B1-5  v i rus ;  CMV,  cy tomega lov i rus ;  H I ,  haemagg lut inat ion  inh ib i t ion  tes t ;  + ,  pos i t ive  tes t  resu l t ;  - ,  negat ive  tes t  resu l t ;  *, not  
tes ted  
Screening for islet cell antibodies (ICA ) 
Sere  were  tes ted  by  the  s tandard  ind i rec t  immunof luorescence  tes t  
us ing  4 b tm cryostat  sect ions  o f  human b lood  group 0 pancreas  as  
prev ious ly  descr ibed  [16] .  Pos i t ive  sera  were  then  tes ted  unt i l  end-  
po in t  d i lu t ions .  In  an  in ternat iona l  qua l i ty  cont ro l  assessment  a t  p r i -  
mary  sc reen ing  our  laboratory  ach ieved  va lues  o f  100  % for  cons is -  
tency ,  sens i t iv i ty ,  spec i f i c i ty ,  and  va l id i ty  (Second Juven i le  D iabetes  
Workshop ICA  Pro f i c iency  Program;  Lab  ID  NO.  116 ,  WAS) .  ICA  
tes t  resu l ts  were  t rans fer red  to  Juven i le  D iabetes  Foundat ion  ( JDF)  
un i ts  us ing  the  s tandard  curve  prov ided  fo r  the  workshop [17] .  The  
lower  l im i t  o f  detect ion  in  our  assay  up  to  now is  5 JDF  un i ts  w i th  a 
laboratory  spec i f i c i ty  and  cons is tency  o f  100  % (F i f th  IDW ICA-  
P ro f i c iency  Program) .  A pos i t ive  ICA  resu l t  was  de f ined  by  rep l i -  
ca te  t i t res  o f  10  JDF  un i ts  o r  g reater .  The  tes ts  were  car r ied  out  in  a 
b l inded  manner  by  two invest igators  (G .  T.  and  G.  G . ) .  
ICA-pos i t ive  sera  were  fu r ther  tes ted  fo r  complement  f i x ing -  
ICA  us ing  an  ind i rec t  immunof luorescent  method as  descr ibed  [16] .  
Virus-specific antibody responses 
Coxsack ie  B v i rus  spec i f i c  IgM responses  were  detected  by  an  
M-ant ibody  capture  EL ISA  techn ique  employ ing  monova lent  
reagents  to  coxsack ie  B1-5  v i ruses  as  prev ious ly  descr ibed  [5].  Ant i -  
bod ies  to  rube l la  v i rus  were  detected  by  a haemagg lut inat ion  inh ib i -  
t ion  tes t  (H I )  us ing  hepar in -MnC12 and ch ick  ery throcytes  as  de-  
W. A. Scherbaum etal.: Virus antibodies and [CA-positivity in non-diabetic individuals 
scribed in detail elsewhere [18]. To confirm rubella HI results, a 
commercial single radial haemolysis (SRH) test was performed 
(Dr. W. Koch/Dr. C. Merk, Ochsenhausen, FRG). Rubella IgM anti- 
bodies were measured by a commercial ELISA (Rubazyme-M-Test, 
Abbot, Wiesbaden, FRG). 
IgM antibodies to cytomegalovirus were detected by the cyto- 
megalovirus-IgG-ELA (Medac, Hamburg, FRG)  and cytomegalo- 
virus-IgA antibodies, by a commercialindirect immunofluorescence 
test (Viramed, Martinsried, FRG). Only cytomegalovirus-IgG posi- 
tive sera were t sted for cytomegalovirus-IgA. Anti-Mumps anti- 
bodies of the IgG- and IgM type were t sted by separate commercial 
ELISA's (Enzygnost-Parotitis, Behringwerke, Marburg, FRG). 
Anti-mumps IgM positive sera were tested by a second ELISA 
(mumps-IgM-ELA, Medac, Hamburg, FRG). Anti-mumps IgA 
antibodies were d tected by indirect immunofluorescence test 
(Viramed, Martinsried, FRG). Only sera positive foranti-mumps 
IgG were tested for anti-mumps IgA. 
The above-mentioned tests were all conducted and interpreted 
according to the manufacturer's instructions. 
Statistical analysis 
Fisher's exact test (two-tail) was applied to compare the antibody 
frequences ofICA-positive and ICA-negative control subjects. 
Results 
Most of the overall data on anti-viral antibodies in the 44 
non-diabetic ICA-positive individuals and their ICA- 
negative matched control subjects are given in Table 1. Of 
35 ICA-positive individuals who answered a specific 
questionaire, 25 had been vaccinated for mumps and ru- 
bella virus 3 to 12 years prior to ICA testing. 
The difference between coxsackie B1-5 specific IgM 
responses in the ICA-positive and ICA-negative control 
subjects was not statistically significant. No increase of 
anti-coxsackie B1-5 IgM responses could be found in the 
six individuals with CF-ICA; only two of the six were posi- 
tive for anti-coxsackie B l -5  IgM. The median age of the 
coxsackie B1-5 IgM-positive individuals was 12.1 years 
(range: 7-19 years) in the ICA-positive probands, and 
12.0 years (range: 7-16 years) in the control subjects. 
There were no increases in anti-mumps-IgM, anti- 
mumps-IgA, anti-cytomegalovirus-IgA, anti-cytomegalo- 
virus-IgG or anti-rubella ntibodies in ICA-positive as 
compared to control subjects. 
Discussion 
Islet cell antibodies indicating an autoimmune r action to 
islet cells, are known to precede the onset of Type 1 
diabetes by months or even years [10-14]. Assuming that 
viruses may play a role in the direct initiation of autoim- 
mune insulitis, the association of recent virus infections 
with the appearance of ICA in the pre-diabetic period 
rather than at the onset of disease should be noted. Precise 
matching of patients and control subjects by area of 
residence is often difficult to achieve, particularly when 
the group studied consists of hospital in-patients [5]. The 
requirements for appropriate control subjects are ideally 
837 
met in our study where age- and sex-matched class-mates 
of the probands were used. 
This study provided no evidence of an association be- 
tween the presence of ICA and recent mumps, post- 
natally acquired rubella or cytomegalovirus infection. In 
previous tudies no association between these virus infec- 
tions and the onset of Type 1 diabetes was found [5-7]. Al- 
though mumps infection may result in transient ICA, islet 
cell surface antibodies and insulin-autoantibody respon- 
ses [t9-20], and may occasionally cause Type i diabetes 
[21], there is little evidence that these viruses are a signifi- 
cant cause of Type 1 diabetes. 
The results of a low prevalence of IgM antibodies to the 
rubella and mumps viruses are not unexpected since IgM 
antibodies to these non-persistent viruses appear almost 
exclusively at primary infection. This is important in light 
of the fact that the prevalence of mumps or rubella im- 
munity at age 13 was 76 % before the vaccination era, and 
71% of our pupils who responded to a questionaire had 
been vaccinated previously. The low prevalence of recent 
infections in our cohort is also supported by the methodo- 
logically-unrelated measurement of IgA antibodies to 
mumps and cytomegalovirus. 
Results of coxsackie B virus-specific IgM studies were 
less clear. Although the difference in prevalence between 
ICA positive and negative individuals was not statistically 
significant, a study of larger numbers would be required to 
exclude such an association. A number of serological 
studies have found a higher prevalence of coxsackie 
B virus-specific IgM responses in patients at Type 1 
diabetes onset compared with control subjects [5, 8, 9, 22] 
while others have not [6-7]. In one study, the prevalence of 
IgM among Type i diabetic patients showed considerable 
geographic and temporal variation, ranging from 0-76 % 
[9]. This probably reflects fluctuations inthe prevalence of
pancreotropic and diabetogenic strains of coxsackie 
B viruses. A clearer understanding of the role of cox- 
sackie B and other enteroviruses in the pathogenesis of
Type 1 diabetes is likely to require longitudinal study of 
ICA-positive subjects and other susceptible individuals, 
such as first-degree relatives of Type 1 diabetic patients. 
This would allow evidence of virus infections to be studied 
in relation to the appearance, rather than the presence of 
ICA and other pre-diabetic markers. 
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